Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre,first-in-patient,dose-escalation and dose-expansion,phase 1b trial |
| |
| Institution: | 1. Swedish Cancer Institute, Seattle, WA, USA;2. Massachusetts General Hospital Cancer Center, Boston, MA, USA;3. Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center, Nashville, TN, USA;4. Cleveland Clinic, Cleveland, OH, USA;5. Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland;6. Faculty of Biomedical Sciences, Universita della Svizzera Italiana, Lugano, Switzerland;7. Stephenson Cancer Center, Oklahoma City, OK, USA;8. Stony Brook University Hospital, Stony Brook, NY, USA;9. University of Wisconsin Carbone Cancer Center, Madison, WI, USA;10. Memorial Sloan Kettering Cancer Center, New York, NY, USA;11. MEI Pharma, San Diego, CA, USA |
| |
| Abstract: | |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
